Get the Stockscreener App
3.7788
2.41%
0.0888
Cellectar Biosciences Inc stock is traded at $3.7788, with a volume of 13,343.
It is up +2.41% in the last 24 hours and up +12.80% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$3.69
Open:
$3.7
24h Volume:
13,343
Relative Volume:
0.09
Market Cap:
$16.02M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-1.1627
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
+9.53%
1M Performance:
+12.80%
6M Performance:
+718.45%
1Y Performance:
+157.06%
1-Day Range:
$3.61
$3.83
1-Week Range:
$3.3001
$3.83
52-Week Range:
$0.224
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.7788 | 15.65M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Will Cellectar Biosciences Inc. (NV4) stock maintain strong growthJuly 2025 Price Swings & Verified Trade Idea Suggestions - Newser
Is Cellectar Biosciences Inc. (NV4) stock supported by strong fundamentalsPrice Action & High Accuracy Trade Alerts - Newser
How reliable is Cellectar Biosciences Inc. (NV4) stock dividend growthDip Buying & Stock Portfolio Risk Management - Newser
Why retail investors pile into Cellectar Biosciences Inc. stockGap Down & Advanced Swing Trade Entry Alerts - Newser
Will Cellectar Biosciences Inc. (NV4) stock deliver compounding returnsWeekly Trend Summary & Advanced Swing Trade Entry Alerts - Newser
Critical Analysis: Cellectar Biosciences (NASDAQ:CLRB) & Agilent Technologies (NYSE:A) - Defense World
How strong is Cellectar Biosciences Inc. (NV4) stock earnings growthEarnings Overview Summary & Weekly Top Stock Performers List - Newser
Can Cellectar Biosciences Inc. (NV4) stock retain market dominanceTrade Risk Assessment & Advanced Swing Trade Entry Plans - Newser
Is Cellectar Biosciences Inc. stock attractive for ETFs2025 Major Catalysts & Verified High Yield Trade Plans - Newser
Cellectar Biosciences (CLRB) Stock Analysis Report | Financials & Insights - Benzinga
Is Cellectar Biosciences Inc. stock dividend yield sustainableQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - BỘ NỘI VỤ
What drives Cellectar Biosciences Inc stock priceResistance Zone Identification & Affordable Stock Picks - earlytimes.in
Will Cellectar Biosciences Inc. stock benefit from sector rotationJuly 2025 Volume & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
Cellectar Biosciences Reports Q3 2025 Financial Progress - MSN
Is Cellectar Biosciences Inc. stock near bottom after decline2025 Macro Impact & Breakout Confirmation Trade Signals - newser.com
CLRB warrants resale, going concern warning and WM drug milestones - Stock Titan
Is Cellectar Biosciences Inc. (NV4) stock a top dividend aristocrat candidate2025 Geopolitical Influence & Intraday High Probability Alerts - newser.com
Why Cellectar Biosciences Inc. stock could outperform in 2025Portfolio Value Report & Accurate Buy Signal Notifications - newser.com
Cellectar signals 2027 global launch for iopofosine as regulatory momentum accelerates - MSN
Using R and stats models for Cellectar Biosciences Inc. forecastingTrade Entry Report & Expert Curated Trade Setup Alerts - newser.com
How Cellectar Biosciences Inc. stock performs in stagflationEarnings Risk Summary & Weekly Top Gainers Alerts - newser.com
Is Cellectar Biosciences Inc. (NV4) stock supported by free cash flowJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
Will Cellectar Biosciences Inc. stock outperform tech sector in 2025Rate Cut & Weekly Chart Analysis and Trade Guides - newser.com
Will Cellectar Biosciences Inc. bounce back from current supportJuly 2025 Drop Watch & Capital Protection Trading Alerts - newser.com
Is Cellectar Biosciences Inc. stock a top pick in earnings seasonEarnings Summary Report & Accurate Entry/Exit Alerts - newser.com
How geopolitical tensions affect Cellectar Biosciences Inc. stock - newser.com
Can Cellectar Biosciences Inc. stock hit record highs againWeekly Trade Review & Capital Efficient Trading Techniques - newser.com
How hedge fund analytics apply to Cellectar Biosciences Inc. stockPortfolio Value Report & Free Accurate Trade Setup Notifications - newser.com
Is Cellectar Biosciences Inc. stock positioned for long term growthJuly 2025 Summary & Proven Capital Preservation Methods - newser.com
What valuation ratios show for Cellectar Biosciences Inc. (NV4) stockPortfolio Value Summary & Low Risk High Reward Trade Ideas - newser.com
Will Cellectar Biosciences Inc. (NV4) stock beat growth indexes2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Using RSI to spot recovery in Cellectar Biosciences Inc.July 2025 Action & Target Return Focused Picks - newser.com
Can Cellectar Biosciences Inc. hit a new high this monthInsider Selling & High Yield Stock Recommendations - newser.com
Is now a turning point for Cellectar Biosciences Inc.Trade Exit Summary & Weekly Breakout Watchlists - newser.com
Using data filters to optimize entry into Cellectar Biosciences Inc.Weekly Trend Summary & Weekly High Return Stock Opportunities - newser.com
Is Cellectar Biosciences Inc. stock a bargain at current levelsWeekly Earnings Recap & Stepwise Swing Trade Plans - newser.com
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cellectar Biosciences Inc Stock (CLRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
| Longcor Jarrod | Chief Operating Officer |
Jan 10 '25 |
Buy |
0.28 |
30,000 |
8,400 |
83,141 |
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):